Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

July 31, 2030

Study Completion Date

July 31, 2030

Conditions

Cutaneous Sarcoma

Interventions

DRUG

Pembrolizumab

Outpatient infusion

Trial Locations (1)

RECRUITING

Moffitt Cancer Center, Tampa

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT07007273 - Pembrolizumab for Advanced Cutaneous Sarcomas Not Including Angiosarcoma | Biotech Hunter | Biotech Hunter